AbbVie’s Crohn’s combo outperformed Skyrizi alone in Phase 2a trial

on

AbbVie reported positive Phase 2a results for ABBV-466, an investigational combination of Skyrizi (risankizumab) and trosunilimab, in 300 people with moderate-to-severe Crohn’s disease.

At week 12, 30.2% of combination-treated patients achieved endoscopic remission, compared with 21.3% on Skyrizi alone and 18.0% on trosunilimab alone. At week 24, rates were 40.5%, 22.4% and 20.0%, respectively.

Serious adverse-event rates were broadly similar:
10.4% with the combination, 9.6% with Skyrizi alone and 9.0% with trosunilimab alone. Common reported events included Crohn’s symptoms and nausea in the combination arm.

The findings suggest that targeting two pathways may improve outcomes, but they come from a mid-stage study and need confirmation in larger trials. ABBV-466 remains investigational; its safety and efficacy have not been established by regulators.

Sources:

www.fiercebiotech.com · biotech · abbvies-next-genAbbVie’s next-gen Crohn’s disease combo beats Skyrizi in ...

As AbbVie's Crohn's combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision

Results With SKYRIZI® (risankizumab-rzaa) for Crohn's ...

SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) ...

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM ...

AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease

AbbVie Presents New Phase 3 AFFIRM Data Showing ...

AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints

Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease

AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary ...

SKYRIZI | Untitled Letter | 9.9.2025

70.2% of evaluable people with moderate-to-severe Crohn’s responded to AbbVie’s drug within 12 weeks, interim results show.

AbbVie Reports 35.8% Endoscopic Remission With ...

Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year